iShares Biotechnology ETF
921 hedge funds and large institutions have $7.04B invested in iShares Biotechnology ETF in 2026 Q1 according to their latest regulatory filings, with 69 funds opening new positions, 270 increasing their positions, 289 reducing their positions, and 92 closing their positions.
3.53% more ownership
Funds ownership: 82.98% → 86.51% (+3.5%)
1% more capital invested
Capital invested by funds: $6.94B → $7.04B (+$98.9M)
7% less repeat investments, than reductions
Existing positions increased: 270 | Existing positions reduced: 289
4% less funds holding
Funds holding: 956 → 921 (-35)
25% less first-time investments, than exits
New positions opened: 69 | Existing positions closed: 92
33% less funds holding in top 10
Funds holding in top 10: 12 → 8 (-4)
47% less call options, than puts
Call options by funds: $102M | Put options by funds: $193M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$361M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$121M |
| 3 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
+$94M |
| 4 |
D.E. Shaw & Co
New York
|
+$59.8M |
| 5 |
BNP Paribas Financial Markets
Paris,
France
|
+$50.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
-$157M |
| 2 |
Corient Private Wealth
Miami,
Florida
|
-$97.5M |
| 3 |
Morgan Stanley
New York
|
-$73.6M |
| 4 |
LPL Financial
San Diego,
California
|
-$45.8M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$41.5M |
IBB Hedge Fund Activity: Q1 2026 in Review
921 of the 8,173 institutional investors tracked by Wall St. Rank reported a position in iShares Biotechnology ETF (IBB) for Q1 2026, worth a combined $7.04B — up 1.4% from $6.94B a quarter earlier.
Sellers outnumbered buyers: 92 funds closed out of IBB and 69 opened new positions — a net loss of 23 holders — while 289 trimmed existing stakes and 270 added.
The largest buyer was JP Morgan Chase, adding an estimated $361M. The largest seller was Two Sigma Investments, cutting an estimated $157M.
- 921 institutional investors held iShares Biotechnology ETF (IBB) as of Q1 2026, down from 956 in Q4 2025.
- Funds reported $7.04B of iShares Biotechnology ETF stock for Q1 2026, up 1.4% quarter-over-quarter.
- 69 funds opened new iShares Biotechnology ETF positions in Q1 2026 and 92 closed out, a net change of -23 holders.
- The largest iShares Biotechnology ETF buyer in Q1 2026 was JP Morgan Chase, an estimated $361M added.
- The largest iShares Biotechnology ETF seller in Q1 2026 was Two Sigma Investments, an estimated $157M sold.
Based on aggregated 13F filings for Q1 2026.